Latest & greatest articles for sumatriptan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sumatriptan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sumatriptan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sumatriptan

1. Sumatriptan

Sumatriptan Top results for sumatriptan - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for sumatriptan The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

2. Bilateral Renal Infarctions During the Use of Sumatriptan Full Text available with Trip Pro

Bilateral Renal Infarctions During the Use of Sumatriptan 30197992 2019 02 26 2468-0249 3 5 2018 Sep Kidney international reports Kidney Int Rep Bilateral Renal Infarctions During the Use of Sumatriptan. 1233-1236 10.1016/j.ekir.2018.05.003 Abramovitz Blaise B Renal Electrolyte and Hypertension Division, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Leonberg-Yoo Amanda A Renal Electrolyte and Hypertension Division, Perelman School of Medicine

2018 Kidney international reports

3. Sumatriptan for the treatment of acute migraine attacks

Sumatriptan for the treatment of acute migraine attacks '); } else { document.write(' '); } ACE| Sumatriptan for the treatment of acute migraine attacks Search > > Sumatriptan for the treatment of acute migraine attacks - Sumatriptan for the treatment of acute migraine attacks Published on 3 May 2017 Guidance Recommendations Following an evaluation of sumatriptan for the treatment of acute migraine attacks, sumatriptan 50mg tablet is recommended for listing on the MOH Standard Drug List 2 (SDL2 (...) ) by the MOH Drug Advisory Committee in view of its clinically superior outcomes when used in combination with naproxen compared with either sumatriptan or naproxen monotherapy, and the low cost of subsidy. This recommendation means that subsidies will apply to sumatriptan for the indications registered in Singapore: Acute relief of migraine attacks with or without aura, including the acute treatment of migraine attacks associated with the menstrual period in women. Quicklinks | | | | | Copyrights © 2019

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

4. Reduced efficacy of sumatriptan in migraine with aura vs without aura (Abstract)

Reduced efficacy of sumatriptan in migraine with aura vs without aura To determine whether acute migraine treatment outcome is different in migraine with aura compared with migraine without aura.We examined pooled outcome data for sumatriptan treatment of migraine with and without aura from the sumatriptan/naratriptan aggregate patient database. We also examined similar outcome data for inhaled dihydroergotamine (DHE) from a single, large randomized controlled study.The pooled pain-free rates 2 (...) hours postdose for sumatriptan 100 mg were significantly higher in patients treating attacks without aura (32%) compared with the group who treated attacks with aura (24%) (p < 0.001). The relative risk for pain freedom 2 hours postdose for attacks without aura was 1.33 (95% confidence interval: 1.16-1.54). The number needed to treat for 2 hours of pain freedom was 4.4 for attacks without aura and 6.2 for attacks with aura. For the clinical trial of DHE, the 2-hour pain-free rates did not differ

2015 EvidenceUpdates Controlled trial quality: uncertain

5. Is Subcutaneous Sumatriptan an Effective Treatment For Adults Presenting to the Emergency Department With Acute Migraine Headache?

Is Subcutaneous Sumatriptan an Effective Treatment For Adults Presenting to the Emergency Department With Acute Migraine Headache? SystematicReviewSnapshot TAKE-HOME MESSAGE Subcutaneous sumatriptan provides effective treatment of migraine headaches, quickly eliminating pain and associated symptoms; however, it has yet to be proven as an optimal emergency department (ED) treatment modality because of inadequate evidence of effectiveness in this setting, increased self-limiting adverse events (...) with subcutaneous su- matriptan to treat a migraine headache episode. DATA EXTRACTION AND SYNTHESIS Two review authors indepen- dently extracted data. Disagree- ments were resolved with the help of a third author. Relative risk was calculated with a ?xed- effect model. Numbers needed to treat were estimated with the Cook and Sackett 1 method. The quality of evidence was assessed using the Oxford Quality Scale. Is Subcutaneous Sumatriptan an Effective Treatment for Adults Presenting to the Emergency Department

2013 Annals of Emergency Medicine Systematic Review Snapshots

6. Randomized Trial of Sumatriptan and Naproxen Sodium Combination in Adolescent Migraine Full Text available with Trip Pro

Randomized Trial of Sumatriptan and Naproxen Sodium Combination in Adolescent Migraine Treatment of adolescent migraine remains a significant unmet medical need. We compared the efficacy and safety of 3 doses of sumatriptan and naproxen sodium (suma/nap) combination tablets to placebo in the acute treatment of adolescent migraine.This randomized, parallel group study in 12 to 17 year olds required 2 to 8 migraines per month (typically lasting >3 hours untreated) for ≥ 6 months. Subjects entered

2012 EvidenceUpdates Controlled trial quality: predicted high

7. WITHDRAWN: Oral sumatriptan for acute migraine. (Abstract)

WITHDRAWN: Oral sumatriptan for acute migraine. Migraine is a common neurovascular disorder characterized by recurrent episodes of disabling headache, autonomic nervous system dysfunction, and, in some patients, neurological aura symptoms. Sumatriptan is one of a class of selective serotonin 5-hydroxytryptamine (5-HT1B/1D) agonists (triptans) thought to relieve migraine attacks by several mechanisms, including cranial vasoconstriction and peripheral and central neural inhibition.To describe (...) and assess the evidence from randomized controlled trials (RCTs) concerning the efficacy and tolerability of oral sumatriptan for the treatment of a single acute attack of migraine in adults.We searched the Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 4, 2001), MEDLINE (1966 through November 2001), and reference lists of articles and books.We included double-blind RCTs comparing oral sumatriptan (100 mg, 50 mg, 25 mg) with placebo, no intervention, other drug treatments

2012 Cochrane

8. Sumatriptan Galpharm

Sumatriptan Galpharm 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged London, 23 November 2011 EMA/40740/2012 Assessment Report Sumatriptan Galpharm 50 mg Tablets International non proprietary name: sumatriptan Procedure No. EMEA/H/C (...) /002140 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Sumatriptan 50 mg Tablets Perrigo Assessment Report EMA/40740/2012 Page 2/43 Table of contents 1 3 Background information on the procedure 1.1 3 Submission of the dossier 1.2 5 Steps taken for the re-examination of the product 2 5 Scientific discussion 2.1 5 Introduction 2.2 6 Quality aspects 2.3 10 Non- Clinical aspects 2.4 11 Clinical Aspects 2.5 21 Pharmacovigilance 3 25 Benefit-Risk

2012 European Medicines Agency - EPARs

9. Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan Full Text available with Trip Pro

Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan Multiple parenteral medications are used to treat migraine and other acute primary headaches in the emergency department (ED). Regardless of specific headache diagnosis, no medication eliminates the frequent recurrence of primary headache after ED discharge. It is uncertain which medication primary headache patients should be given on discharge from an ED. The aim (...) of this study is to compare the efficacy of oral sumatriptan with naproxen for treatment of post-ED recurrent primary headache.This was a randomized, double-blind efficacy trial. We randomized patients to either naproxen 500 mg or sumatriptan 100 mg for headache recurrence after ED discharge. Patients were eligible if they received parenteral therapy for an acute exacerbation of a primary headache in the ED. Patients who met established criteria for migraine without aura were designated a priori

2010 EvidenceUpdates Controlled trial quality: predicted high

10. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department (Abstract)

A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department Intravenous (IV) prochlorperazine with diphenhydramine is superior to subcutaneous sumatriptan in the treatment of migraine patients presenting to the emergency department (ED).In this randomized, double-blind, placebo-controlled trial, after providing written informed consent, patients presenting to the ED with a chief complaint of migraine (...) received a 500-mL bolus of IV saline solution and either 10 mg prochlorperazine with 12.5 mg diphenhydramine IV plus saline solution placebo subcutaneously or saline solution placebo IV plus 6 mg sumatriptan subcutaneously. Pain intensity was assessed with 100-mm visual analog scales (visual analog scale at baseline and every 20 minutes for 80 minutes). The primary outcome was change in pain intensity from baseline to 80 minutes or time of ED discharge if subjects remained in the ED for fewer than 80

2010 EvidenceUpdates Controlled trial quality: predicted high

11. Alsuma (sumatriptan) injection

Alsuma (sumatriptan) injection Drug Approval Package: Alsuma (sumatriptan) NDA #022377 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Alsuma (sumatriptan) 6mg/0.5ml injection Company: King Pharmaceuticals, Inc. Application No.: 022377 Approval Date: 06/29/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created

2010 FDA - Drug Approval Package

12. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life (Abstract)

Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life To evaluate efficacy and tolerability of a single, fixed-dose tablet of sumatriptan 85 mg/naproxen sodium 500 mg (sumatriptan/naproxen sodium) vs placebo in migraineurs who had discontinued treatment with a short-acting triptan because of poor response or intolerance.Triptan monotherapy is ineffective or poorly tolerated in 1 of 3 migraineurs and in 2 of 5 migraine attacks. In April, 2008, the Food (...) and Drug Administration approved the combination therapy sumatriptan/naproxen sodium, developed specifically to target multiple migraine mechanisms. This combination product offers an alternative migraine therapy for patients who have reported poor response or intolerance to short-acting triptans.Two replicate, randomized, multicenter, double-blind, placebo-controlled, 2-attack crossover trials evaluated migraineurs who had discontinued a short-acting triptan in the past year because of poor response

2009 EvidenceUpdates Controlled trial quality: uncertain

13. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine (Abstract)

Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine Research suggests treating a migraine at the first sign of pain increases the likelihood of the best clinical outcome.To investigate the efficacy and tolerability of a fixed-dose, single-tablet formulation of sumatriptan 85 mg, formulated with RT Technology, and naproxen sodium 500 mg (sumatriptan/naproxen) as early intervention acute therapy for migraine.Patients (aged 18 to 65 years (...) ) with International Headache Society-defined migraine with or without aura were enrolled in one of two identically designed, randomized, double-blind, parallel group, placebo-controlled studies. Patients treated a single migraine within 1 hour of onset of migraine head pain and while the pain was mild with either sumatriptan/naproxen or placebo. The primary efficacy measure was the percentage of patients who became pain-free 2 hours postdose.Intent-to-treat analyses consisted of 576 and 535 migraineurs. At 2

2008 EvidenceUpdates Controlled trial quality: predicted high

14. Treximet (sumatriptan and naproxen sodium)

Treximet (sumatriptan and naproxen sodium) Drug Approval Package: Treximet (sumatriptan and naproxen sodium) NDA #021926 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Treximet (sumatriptan and naproxen sodium) Tablets Company: Pozen Inc. Application No.: 021926 Approval Date: 04/15/2008 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) Medical Review(s) (PDF

2008 FDA - Drug Approval Package

15. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. Full Text available with Trip Pro

Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. Multiple pathogenic mechanisms may be involved in generating the migraine symptom complex, and multimechanism-targeted therapy may confer advantages over monotherapy.To evaluate the efficacy and safety of a fixed-dose tablet containing sumatriptan succinate and naproxen sodium relative to efficacy and safety of each monotherapy and placebo for the acute treatment of migraine.Two replicate, randomized, double-blind, single (...) -attack, parallel-group studies conducted among 1461 (study 1) and 1495 (study 2) patients at 118 US clinical centers who were diagnosed as having migraine and received study treatment for a moderate or severe migraine attack.Patients were randomized in a 1:1:1:1 ratio to receive a single tablet containing sumatriptan, 85 mg, and naproxen sodium, 500 mg; sumatriptan, 85 mg (monotherapy); naproxen sodium, 500 mg (monotherapy); or placebo, to be used after onset of a migraine with moderate to severe

2007 JAMA Controlled trial quality: predicted high

16. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine

Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine Zhang L, Hay J W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three technologies for the treatment of migraine were studied. These were rizatriptan 10 mg, sumatriptan 50 mg, and a fixed-dose combination of ergotamine tartrate plus caffeine (Cafergot) 2 mg/200 mg. Cafergot was used as the comparator. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population

2005 NHS Economic Evaluation Database.

17. A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point

A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point Williams P, Reeder C E Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of almotriptan 12.5 mg versus two dosing levels of sumatriptan (50 mg and 100 mg) for the treatment of an acute migraine attack. Type of intervention Treatment. Economic study type

2004 NHS Economic Evaluation Database.

18. Imitrex (Sumatriptan)

Imitrex (Sumatriptan) Drug Approval Package: Imitrex (Sumatriptan) NDA #020132s015 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Imitrex (Sumatriptan) Tablets Company: GlaxoSmithKline Application No.: 020132s015 Approval Date: 06/30/2003 (PDF) (PDF) (PDF) (PDF) (PDF) Date created: May 052006 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing information in different file formats, see . Language

2003 FDA - Drug Approval Package

19. Costs and outcomes of early versus delayed migraine treatment with sumatriptan

Costs and outcomes of early versus delayed migraine treatment with sumatriptan Costs and outcomes of early versus delayed migraine treatment with sumatriptan Costs and outcomes of early versus delayed migraine treatment with sumatriptan Halpern M T, Lipton R B, Cady R K, Kwong W J, Marlo K O, Batenhorst A S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of early sumatriptan treatment for mild migraine versus delayed sumatriptan treatment for moderate to severe migraine. Doses of 50 mg or 100 mg were considered for both treatments. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of patients experiencing mild migraine

2002 NHS Economic Evaluation Database.

20. Economic implications of early treatment of migraine with sumatriptan tablets

Economic implications of early treatment of migraine with sumatriptan tablets Economic implications of early treatment of migraine with sumatriptan tablets Economic implications of early treatment of migraine with sumatriptan tablets Cady R K, Sheftell F, Lipton R B, Kwong W J, O'Quinn S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The early treatment of migraine with sumatriptan was studied. Two dosages, 50 and 100 mg, were considered. These were administered when the pain was mild. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of 1,000 patients suffering from mild migraine. All patients had a diagnosis of migraine

2001 NHS Economic Evaluation Database.